E2 ModeratePreliminaryPEM not requiredLongitudinalPeer-reviewedReviewed
Standard · 3 min
Cognitive dysfunction and mental fatigue in childhood chronic fatigue syndrome--a 6-month follow-up study.
Kawatani, Junko, Mizuno, Kei, Shiraishi, Seishi et al. · Brain & development · 2011 · DOI
Quick Summary
This study looked at thinking and attention problems in children with ME/CFS using a specialized test that measures how quickly and accurately the brain can process information. Children with ME/CFS performed worse on attention tasks compared to healthy children, especially when they had to switch between different tasks. After 6 months of combined treatment with therapy and medication, children showed improvements in both their thinking ability and fatigue levels.
Why It Matters
This study demonstrates that cognitive dysfunction—particularly in attention switching and working memory—is measurable and may be a neurobiological feature of pediatric ME/CFS. The finding that treatment improvements correlate with improved attention performance suggests that cognitive deficits are not simply psychological but may reflect underlying neurological changes worth investigating further.
Observed Findings
Alternative attention reaction time differences could discriminate CCFS patients from controls with 70.5% accuracy (P=0.007)
CCFS patients showed significantly lower alternative attention performance before treatment (P=0.037)
Charlder's fatigue scores were significantly higher in CCFS patients before treatment (P=0.002)
Performance status improved significantly over 6 months with combined treatment (P<0.001)
Improvement in cognitive symptoms correlated strongly with improvement in alternative attention (r=0.653, P=0.002)
Inferred Conclusions
Higher-order cognitive dysfunction, particularly in alternative attention, is a characteristic feature of pediatric ME/CFS
Combined CBT and pharmacotherapy may effectively improve cognitive and fatigue symptoms in childhood ME/CFS
Alternative attention performance measured by mATMT may serve as a biomarker to monitor treatment response in pediatric ME/CFS patients
Remaining Questions
Which specific medication(s) were used and what were their individual effects on cognitive function?
Does improvement in attention represent recovery of cognitive function or behavioral compensation through treatment?
What This Study Does Not Prove
This study does not establish which components of combined treatment (CBT, medication, or both) drive improvement, nor does it prove that attention deficits cause fatigue or vice versa—only that they co-occur and may improve together. The small sample size and lack of control groups receiving only CBT or only medication limit generalizability. It also does not clarify whether cognitive dysfunction is primary to ME/CFS pathogenesis or secondary to fatigue and deconditioning.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Contribute
Private, reviewed by a human. Not a public comment thread.